Morphic Medical, Inc.
GIDYL
OTC PK
| 03/31/2021 | 12/31/2020 | 09/30/2020 | 06/30/2020 | 03/31/2020 | |
|---|---|---|---|---|---|
| Net Income | -29.60% | 49.71% | -28.35% | 0.32% | -14.51% |
| Total Depreciation and Amortization | 616.67% | -14.29% | 0.00% | -83.33% | 425.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -27.74% | -66.86% | 152.15% | 10.54% | 796.30% |
| Change in Net Operating Assets | -1.87% | 276.32% | 91.44% | -91.59% | -2,626.47% |
| Cash from Operations | -57.18% | 54.46% | 40.21% | -25.42% | -40.53% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -119.74% | -34.07% | -79.44% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 469.68% | -109.35% | 362.75% | -79.44% | 35.09% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 84.96% | -178.06% | 162.22% | -330.33% | 23.63% |
